Intech Investment Management LLC Purchases 9,088 Shares of Glaukos Co. (NYSE:GKOS)

Intech Investment Management LLC grew its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 79.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,462 shares of the medical instruments supplier's stock after acquiring an additional 9,088 shares during the quarter. Intech Investment Management LLC's holdings in Glaukos were worth $2,666,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Glaukos by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier's stock worth $500,576,000 after purchasing an additional 72,159 shares during the last quarter. Fred Alger Management LLC lifted its stake in shares of Glaukos by 3.8% in the 2nd quarter. Fred Alger Management LLC now owns 1,278,723 shares of the medical instruments supplier's stock worth $151,337,000 after purchasing an additional 47,308 shares during the period. Primecap Management Co. CA boosted its holdings in shares of Glaukos by 43.9% in the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier's stock worth $144,483,000 after buying an additional 372,180 shares during the last quarter. Driehaus Capital Management LLC increased its holdings in Glaukos by 24.0% during the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier's stock valued at $95,112,000 after buying an additional 155,653 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Glaukos in the second quarter worth approximately $67,460,000. 99.04% of the stock is currently owned by institutional investors.

Insider Activity at Glaukos

In other news, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the sale, the director now owns 32,336 shares of the company's stock, valued at approximately $4,225,345.12. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $14,198,425.93. This represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.

Glaukos Price Performance

NYSE GKOS traded up $3.17 during trading on Friday, hitting $144.00. 549,002 shares of the stock traded hands, compared to its average volume of 593,848. The company has a market capitalization of $7.94 billion, a P/E ratio of -47.68 and a beta of 1.02. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $146.09. The firm has a 50-day simple moving average of $132.40 and a 200-day simple moving average of $123.80. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same quarter in the prior year, the firm earned ($0.50) earnings per share. Glaukos's revenue was up 23.9% on a year-over-year basis. As a group, analysts predict that Glaukos Co. will post -1.96 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Piper Sandler set a $140.00 price objective on Glaukos in a research note on Thursday, October 17th. Stifel Nicolaus raised their price objective on Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Needham & Company LLC boosted their price objective on Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a research note on Thursday, August 1st. Wells Fargo & Company raised their target price on shares of Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Finally, BTIG Research raised their price objective on shares of Glaukos from $131.00 to $139.00 and gave the company a "buy" rating in a research report on Wednesday, August 28th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus target price of $134.55.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.